Alaunos Therapeutics, Inc.
TCRT · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $2 | $4 |
| % Growth | – | -100% | -50% | – |
| Cost of Goods Sold | $0 | $185 | $0 | $0 |
| Gross Profit | $0 | -$185 | $2 | $4 |
| % Margin | – | – | 100% | 100% |
| R&D Expenses | $469 | $185 | $347 | -$86 |
| G&A Expenses | $0 | $854 | $747 | $845 |
| SG&A Expenses | $718 | $854 | $747 | $845 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$185 | $0 | $0 |
| Operating Expenses | $1,187 | $854 | $1,094 | $759 |
| Operating Income | -$1,187 | -$1,039 | -$1,092 | -$755 |
| % Margin | – | – | -54,600% | -18,875% |
| Other Income/Exp. Net | $28 | -$12 | $19 | $13 |
| Pre-Tax Income | -$1,159 | -$1,051 | -$1,073 | -$742 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$1,159 | -$1,051 | -$1,073 | -$742 |
| % Margin | – | – | -53,650% | -18,550% |
| EPS | -0.55 | -0.63 | -0.67 | -0.46 |
| % Growth | 12.7% | 6% | -45.7% | – |
| EPS Diluted | -0.55 | -0.63 | -0.67 | -0.46 |
| Weighted Avg Shares Out | 2,183 | 1,676 | 1,601 | 1,601 |
| Weighted Avg Shares Out Dil | 2,183 | 1,676 | 1,601 | 1,601 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | -$1 |
| EBITDA | -$1,159 | -$1,039 | -$1,073 | -$742 |
| % Margin | – | – | -53,650% | -18,550% |